Cell fractionation analyses confirmed that treatment of U87 and T98G cells with 2-BP substantially reduced the levels of endogenous GLUT1 associated with the PM fractions but did not affect total GLUT1 protein levels (Fig
By starting therapy, patients acknowledge that they have discussed potential benefits, risks, and alternatives with a MedClub clinician and agree to ongoing monitoring as recommended
Non sono riportate specifiche controindicazioni, ma consigliabile consultare un professionista sanitario prima dell'uso, specialmente per individui con condizioni mediche preesistenti
Nauck MA, Heimesaat MM, Orskov C et al (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
It falls under Chapter 7 of ICD-10-CM (H00-H59) and is valid and billable for 2026
PubMed laboratory research record [PMID: 36700268] PubMed record related to this compound for laboratory literature review